🧠 Cognitive Decline & Alzheimer's Risk

What this panel can settle, and by what logic

Nine markers doing two unrelated jobs: two of them estimate Alzheimer pathology and risk, and seven of them look for the reversible conditions that imitate it.

1. pTau-217 (AD-Detect) is the strongest blood marker of Alzheimer pathology that exists. Plasma phospho-tau217 separated neuropathologically confirmed Alzheimer disease from other neurodegenerative disorders with an area under the curve of 0.89, reached 0.96 for clinical Alzheimer dementia, and distinguished abnormal from normal tau-PET scans at 0.93 Palmqvist 2020. Those are diagnostic-grade numbers in the populations studied.
2. APOE Genotyping genotype is risk stratification, and one genotype is more than that. In carriers of two copies of e4, abnormal amyloid in cerebrospinal fluid was near-universal by age 65 and 75% had a positive amyloid scan — enough for the authors to argue e4 homozygosity is a distinct genetic form of the disease rather than a risk factor Fortea 2024.
3. The other seven are the reversible list, and they are why the panel is worth buying at any age. Vitamin B12 with Methylmalonic Acid (MMA) finds functional deficiency behind a normal-looking number Harrington 2024; Homocysteine is a modifiable risk factor for brain atrophy Smith 2010; TSH (Thyroid-Stimulating Hormone), HbA1c (Hemoglobin A1c), Vitamin D (25-Hydroxy) and hs-CRP (High-Sensitivity C-Reactive Protein) cover thyroid, glycemic and inflammatory contributors.

What it cannot settle, and what would

A biomarker is not a diagnosis, and this is the distinction the whole panel turns on. Dementia is a clinical syndrome defined by impairment in daily function; pTau-217 (AD-Detect) measures Alzheimer pathology. Those come apart in both directions — pathology is present in cognitively normal people for a decade or more before symptoms, and plenty of impairment has nothing to do with amyloid or tau. The accuracy figures above were established in specialist cohorts against a reference standard Palmqvist 2020, and a positive result in a well 45-year-old buying it out of pocket is a different situation with a different predictive value.

APOE Genotyping tells you what is more likely, never what will happen. Most e4 carriers do not develop Alzheimer dementia and most people who do are not e4 homozygotes Fortea 2024. The result cannot be changed, cannot be treated, and once known cannot be unknown — which is a real consideration for insurance disclosure and for the people you would have to tell.

It cannot identify a non-Alzheimer dementia. Vascular cognitive impairment, dementia with Lewy bodies, frontotemporal dementia and normal-pressure hydrocephalus are diagnosed on history, examination and MRI. A normal pTau-217 (AD-Detect) in a person who is deteriorating means the cause is one of those, not that nothing is wrong.

And it cannot test your memory. Whether cognition has objectively declined is settled by neuropsychological assessment against normative data, ideally repeated. That is the measurement this panel is bought as a substitute for, and it is not one.

Draw conditions that decide whether the money is wasted

Four conditions. The first two protect specific markers; the third protects the whole panel.

1. Stop B12 and B-complex supplements 1 week before. Serum Vitamin B12 follows recent intake, so a supplemented sample reports your tablet rather than your status; Methylmalonic Acid (MMA) is the marker that resists this Harrington 2024. On a panel bought to exclude a reversible cause, hiding the reversible cause is the worst possible failure.
2. Plasma markers are handling-sensitive: get the sample spun and frozen promptly. Delay to centrifugation and storage temperature measurably shift biomarker concentrations Abraham 2019, and pTau-217 (AD-Detect) is the most expensive assay in the panel to have degraded by a courier.
3. Not during or shortly after an acute illness. Infection raises hs-CRP (High-Sensitivity C-Reactive Protein), and acute illness with confusion is a delirium workup rather than a dementia one — a different test on a different day.
4. 72 hours off biotin for the TSH (Thyroid-Stimulating Hormone), since thyroid disease is one of the reversible causes and biotin is the commonest way to get the thyroid result wrong Li 2020. Use one laboratory for Vitamin D (25-Hydroxy) as well Wise 2021.

How you would know it answered your question, and what each pattern means next

Five results, and the honest interval for each. Note that two of these should never be repeated at all.

• pTau-217 (AD-Detect) abnormal: this goes to a memory clinic, not to another blood test. Confirmation is clinical assessment with imaging and usually a cerebrospinal-fluid or PET measure Palmqvist 2020. Repeating the plasma marker in 6 months answers nothing.
• APOE Genotyping e4/e4: never repeat — the genotype is fixed. What changes with it is how hard the modifiable risks are worth treating: blood pressure, ApoB (Apolipoprotein B), HbA1c (Hemoglobin A1c), hearing, activity and sleep Fortea 2024.
• Homocysteine above 10 µmol/L with low-normal B12 or folate: treat and retest at 12 weeks. The trial evidence for slowing atrophy applies to people with raised homocysteine, which is precisely why measuring it first matters Smith 2010.
• Vitamin B12 low-normal with a raised Methylmalonic Acid (MMA): replace, then recheck MMA at 4 weeks Harrington 2024. Cognitive change from B12 repletion, where it happens at all, takes months longer than the biochemistry.
• Everything normal and the symptom is progressing: the reversible list is excluded, and the next step is a clinician with access to imaging and formal cognitive testing.

Sources read for these sections

• Palmqvist S, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020 · PMID 32722745
• Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nature Medicine 2024 · PMID 38710950
• Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010 · PMID 20838622
• Harrington DJ. The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Annals of Clinical Biochemistry 2024 · PMID 39367523
• Chen Z, et al. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine 2022 · PMID 36382101
• Wise SA, et al. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias. Journal of Steroid Biochemistry and Molecular Biology 2021 · PMID 34010687
• Abraham RA, et al. Effect of temperature and time delay in centrifugation on stability of select biomarkers of nutrition and non-communicable diseases in blood samples. Biochemia Medica 2019 · PMID 31223262
• Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC Guidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med 2020 · PMID 32445355